♥속보♥ 세계최초 위암치료제 완치33명코멘트3

■세계최초"위암차료제 리보세라닙 오늘 ASCO에서 임상발표했다.

오늘 임상발표에서 위암완치자 33명 부분완치 113명.대거 나왔다.

현 리보세라닙은 국내에서 에이치엘비생명과학에서 선치료제로 시판하고있다.

Methods:
Patients older than 18 years with histologically diagnosed with gastric cancer were enrolled and treated with either apatinib alone or in combination with other drugs. The primary endpoint was
progression-free survival (PFS), and
secondary endpoints were overall survival (OS), overall response rate (ORR) and disease control rate (DCR). The adverse events were also recorded.


Results:
From March 2018 to March 2019, a total of 1000 patients were enrolled. Among them, 48(0.48%), 13(0.13%), 225(22.5%), 389 (38.9%), and 325 (32.5%) patients received apatinib as postoperative auxiliary-, neoadjuvant-, first-,
second-, and third- or higher line therapy, respectively. Efficacy evaluation was performed in 901 patients. Thirty-five
patients achieved complete response (CR), 116 patients achieved partial response (PR), 596 patients achieved stable disease (SD), and 154 patients had progressive disease (PD), illustrating an ORR of 16.76% and a DCR of 82.91%. The
mPFS was 5.32 months (95% CI, 4.93-5.75), and mOS was 9.76 months (95% CI, 8.97-10.81). In addition, the mos of apatinib in first-line, second-line, and third-line treatments were 12.68 months, 9.49 months, and 7.62 months,respectively. Patients received apatinib in combination with other drugs had longer survival than apatinib alone, with MPES 5.62 months vs 4.47 months and mos 10.81 months vs 7.95 months. Such phenomenon was also observed in ORR (18.21% VS 13.04%,P<0.001) and DCR (84.88% VS 77.87%,P<0.001). The main adverse events (AE) wer anemia (67.2%), thrombocytopenia (36.2%), leukopenia (34.5%)and anorexia (37.6%). The most common grade 3-4
adverse events included neutropenia, anemia and thrombocytopenia.